Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Scott Weikle

Internal Medicine Travelers Rest, SC Doctor of Osteopathy

NPI 1487618914 CMS profile 248151

6 S Poinsett Hwy, Travelers Rest, SC 29690

Open in the dashboard

General payments

$3,346

196 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Scott Weikle of Travelers Rest, SC is reported in the CMS Open Payments database as having received $3,346 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $827 50
2022 General $852 55
2021 General $192 8
2020 General $214 15
2019 General $1,262 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Weikle
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Scott Weikle were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Scott Weikle Internal Medicine median Middle half National median
2019 $1,262 $159 $48–$570 $163
2020 $214 $119 $33–$402 $114
2021 $192 $135 $37–$521 $132
2022 $852 $141 $42–$496 $149
2023 $827 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $577 31 payments
  2. AstraZeneca Pharmaceuticals LP $496 27 payments
  3. Lilly USA, LLC $282 21 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $238 11 payments
  5. AbbVie, Inc. $230 16 payments
  6. Astellas Pharma US Inc $196 6 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $188 11 payments
  8. Pfizer Inc. $185 14 payments
  9. Amgen Inc. $150 9 payments
  10. Novartis Pharmaceuticals Corporation $143 9 payments
  11. Other $661 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,240 194 payments
  2. Education $106 2 payments
Products named General payments · program years 2019–2023
  1. Ozempic $436 28 payments
  2. FARXIGA $354 24 payments
  3. RYBELSUS $307 18 payments
  4. JARDIANCE Diabetes $209 9 payments
  5. Tresiba $206 6 payments
  6. Kerendia $188 11 payments
  7. MOUNJARO $126 9 payments
  8. FASENRA $115 1 payment
  9. AIMOVIG $112 7 payments
  10. JARDIANCE Diabetes $97 8 payments
  11. Other $2,190 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

13,109

Median for Internal Medicine: 777

Drug cost

$1,373,937

Median for Internal Medicine: $73,373

Branded share of claims

23%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 352 $381,166
Trulicity Dulaglutide Brand 117 $159,094
Eliquis Apixaban Brand 171 $153,331
Ozempic Semaglutide Brand 110 $151,699
Mounjaro Tirzepatide Brand 71 $95,412
Farxiga Dapagliflozin Propanediol Brand 70 $69,683
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 60 $47,145
Rybelsus Semaglutide Brand 42 $43,918
Xarelto Rivaroxaban Brand 31 $40,134
Tresiba Flextouch U-200 Insulin Degludec Brand 45 $31,782

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$149,674

Of which drugs: $10,758

Medicare patients

497

Average age 76

Services billed

5,078

242 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 36%
Diabetes 28%
Ischemic heart disease 25%
Chronic kidney disease 25%
Depression 23%
Atrial fibrillation 18%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 19 19 $5,430
Vaccine for influenza for injection into muscle 90653 Office 63 63 $5,073

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record